

Cancer Association of South Africa (CANSA)



Fact Sheet on Antibiotic Resistance and Cancer Treatment

Introduction

According to Frieden (2013) antibiotic resistance is one of the most serious health threats currently faced by the world. Infections from resistant bacteria are now too common, and some pathogens have even become resistant to multiple types or classes of antibiotics (antimicrobials used to treat bacterial infections).

[Picture Credit: Antibiotics I]



The loss of effective antibiotics will undermine the ability to fight infectious diseases and manage the infectious complications common in vulnerable patients undergoing chemotherapy for cancer, dialysis for renal failure, and surgery, especially organ transplantation, for which the ability to treat secondary infections is crucial.

Frieden (*ibid*) concludes: “When first-line and then second-line antibiotic treatment options are limited by resistance or are unavailable, healthcare providers are forced to use antibiotics that may be more toxic to patients and frequently more expensive and less effective. Even when alternative treatments exist, research has shown that patients with resistant infections are often much more likely to die, and survivors have significantly longer hospital stays, delayed recuperation, and long-term disability.

“Efforts to prevent such threats build on the foundation of proven public health strategies: immunisation, infection control, protecting the food supply, antibiotic stewardship, and reducing person-to-person spread through screening, treatment and education.”

Kreftforeningen, PB 4 Sentrum, 0101 Oslo. 2020. What are the consequences of antibiotic resistance for cancer patients? <https://kreftforeningen.no/antimicrobial-resistance/the-consequences-for-cancer-patients/>

“Bacterial infection is one of the most common complications among cancer patients. A weakened immune system and infections can prove life-threatening for patients with serious diseases. After surgery, many patients require antibiotics to treat infected wounds. Radiation therapy and chemotherapy kill cancer cells, but also cells that are part of our defence mechanism against

infections. This means that patients who receive radiation or chemotherapy often develop infections that require treatment with antibiotics. Transplantations and immunotherapy are also impossible to perform without antibiotics. It is estimated that 1 in 5 cancer patients need antibiotics during their cancer treatment. In Norway, the Oslo University Hospital reports that 20 percent of their cancer patients under treatment receive antibiotics. Some cancer types, such as acute leukemia and bone marrow cancer (multiple myeloma) for example, cannot be treated without antibiotics. Antibiotic resistant bacteria will set cancer treatment back for decades, while the incidence of cancer cases will continue to rise in the years to come. For the patients, this may mean higher mortality, more difficult and more expensive treatment, and many side and late effects. Many treatment options will disappear entirely. Antibiotic resistance will also have major consequences for the patients' interactions with healthcare personnel and family members whereby protective "yellow coats", isolation and confinement rooms will be required."

Montserrat-Martinez, A., Gambin, Y. & Sierecki, I. 2019.

"Since their discovery in the early 20th century, antibiotics have been used as the primary weapon against bacterial infections. Due to their prophylactic effect, they are also used as part of the cocktail of drugs given to treat complex diseases such as cancer or during surgery, in order to prevent infection. This has resulted in a decrease of mortality from infectious diseases and an increase in life expectancy in the last 100 years. However, as a consequence of administering antibiotics broadly to the population and sometimes misusing them, antibiotic-resistant bacteria have appeared. The emergence of resistant strains is a global health threat to humanity. Highly-resistant bacteria like *Staphylococcus aureus* (methicillin-resistant) or *Enterococcus faecium* (vancomycin-resistant) have led to complications in intensive care units, increasing medical costs and putting patient lives at risk. The appearance of these resistant strains together with the difficulty in finding new antimicrobials has alarmed the scientific community. Most of the strategies currently employed to develop new antibiotics point towards novel approaches for drug design based on prodrugs or rational design of new molecules. However, targeting crucial bacterial processes by these means will keep creating evolutionary pressure towards drug resistance. In this review, we discuss antibiotic resistance and new options for antibiotic discovery, focusing in particular on new alternatives aiming to disarm the bacteria or empower the host to avoid disease onset."

Key Facts Around Antibiotic Resistance

The World Health Organization released the following key facts around antibiotic resistance during November 2017:

- Antibiotics are medicines used to prevent and treat bacterial infections. Antibiotic resistance occurs when bacteria change in response to the use of these medicines.
- Bacteria, not humans or animals, become antibiotic-resistant. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria.
- Antibiotic resistance leads to higher medical costs, prolonged hospital stays, and increased mortality.
- The world urgently needs to change the way it prescribes and uses antibiotics. Even if new medicines are developed, without behaviour change, antibiotic resistance will remain a major threat. Behaviour changes must also include actions to reduce the spread of infections through vaccination, hand washing, practising safer sex, and good food hygiene.

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

March 2020

(World Health Organization, 2017).

[Picture Credit: Drug Resistance]



Papanicolas, L.E., Gordon, D.L., Wesselingh, S.L. & Rogers, G.B. 2018.

“The global spread of antibiotic-resistant pathogens threatens to increase the mortality of cancer patients significantly. We propose that chemotherapy contributes to the emergence of antibiotic-resistant bacteria within the gut and, in combination with antibiotics, drives pathogen overgrowth and translocation into the bloodstream. In our model, these processes are mediated by the effects of chemotherapy on bacterial mutagenesis and horizontal gene transfer, the disruption of commensal gut microbiology, and alterations to host physiology. Clinically, this model manifests as a cycle of recurrent sepsis, with each episode involving ever more resistant organisms and requiring increasingly broad-spectrum antimicrobial therapy. Therapies that restore the gut microbiota following chemotherapy or antibiotics could provide a means to break this cycle of infection and treatment failure.”

Contributions Which Individuals and Health Professionals can Make

According to the World Health Organization (*ibid*), individuals and health professionals can make the following contributions:

“Individuals

To prevent and control the spread of antibiotic resistance, individuals can:

- Only use antibiotics when prescribed by a certified health professional.
- Never demand antibiotics if your health worker says you don't need them.
- Always follow your health worker's advice when using antibiotics.
- Never share or use leftover antibiotics.
- Prevent infections by regularly washing hands, preparing food hygienically, avoiding close contact with sick people, practising safer sex, and keeping vaccinations up to date.
- Prepare food hygienically, following the WHO Five Keys to Safer Food (keep clean, separate raw and cooked, cook thoroughly, keep food at safe temperatures, use safe water and raw materials) and choose foods that have been produced without the use of antibiotics for growth promotion or disease prevention in healthy animals.

“Health professionals

To prevent and control the spread of antibiotic resistance, health professionals can:

- Prevent infections by ensuring your hands, instruments, and environment are clean.
- Only prescribe and dispense antibiotics when they are needed, according to current guidelines.
- Report antibiotic-resistant infections to surveillance teams.
- Talk to your patients about how to take antibiotics correctly, antibiotic resistance and the dangers of misuse.

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

March 2020

- Talk to your patients about preventing infections (for example, vaccination, hand washing, safer sex, and covering nose and mouth when sneezing).”

(World Health Organization, 2017).

De Silva, N., Jackson, J. & Steer. 2018.

AIMS: To document patient characteristics, infection types, patterns of antibiotic resistance and outcomes in all patients with cancer requiring inpatient management for suspected infection at a regional Australian cancer centre.

METHODS: We studied patients ≥ 18 years of age who were admitted under the oncology unit at Albury Wodonga Health during a 12-month period and who had a microbiological test performed for suspected infection during their admission. Data were extracted retrospectively from electronic records and analysed through descriptive statistics.

RESULTS: We identified 275 episodes of suspected infection occurring in 208 patients (M/F: 61%/39%). Median age was 68 years, solid tumour 76%, haematological malignancy 24%. A positive culture was obtained in 28% of cases: Gram-positive 48.5% and Gram-negative 51.5%. Drug resistant *Pseudomonas aeruginosa* was seen in 38% (5/13) of pseudomonas isolates, three times the rate seen in general hospital admissions. Extended spectrum beta lactamase was seen in 22% of Gram-negative isolates. Empiric IV antibiotic choice was guideline concordant in 61% of neutropenic fever (NF) (NF) presentations. Only 17% of NF presentations received antibiotics within the recommended hour of emergency department triage. The inpatient mortality rate was 3%. Fifty-seven percent of NF presentations satisfied Multinational Association of Supportive Care in Cancer risk index criteria for outpatient management.

CONCLUSIONS: This is the first study of this type in patients with cancer at an Australian regional cancer centre. The study highlighted key areas for improvement in antibiotic prescription and control of antibiotic resistance at our institution.

Antibiotic Resistance: the Facts

“A major menace looms. In 2017, many more people could begin dying from common bacterial infections. As resistance to antibiotics booms, diseases from gonorrhoea to urinary tract infections are becoming untreatable – a situation that looks set to get worse as the world reaches a new tipping point.” (McKenzie, 2017).

“The world is about to reach the point where more antibiotics will be consumed by farm animals worldwide than by humans. This will mean more resistant bacteria, which could be a big threat. The livestock industry has long played down any risk to human health caused by using antibiotics in farming, but the danger is now accepted, according to the UN Food and Agriculture Organization (FAO).

The UN General Assembly has called for countries to encourage the best use of antibiotics. But it hasn't yet called for specific measures, such as banning their use to assist livestock growth – rather than fight infections – which can promote resistance.”

(*ibid*).

Technology Networks. 2020. Antibiotic Resistance Calls Future of Cancer Treatment Into Question.

“ ‘The effectiveness of cancer treatments threatened by rising antibiotic resistance’ reveals that four in 10 (41%) UK oncologists have seen a rise in drug-resistant infections in the past 12 months and that 95% of them are worried about the impact of “superbugs” on their patients. Almost half (46%) of cancer doctors polled say they believe drug-resistant infections could make chemotherapy unviable. Every day, cancer patients rely on antibiotics for prevention and treatment of infections. This is one of the most common complications of their treatment. Cancer is typically treated with a range of surgical and non-surgical interventions and many of these treatments leave a patient with a weakened immune system and more vulnerable to infection. This is where the risk of multidrug-resistant bacteria rears its head. Revealingly, the oncologists reported that on average 23% of all their patients contract a bacterial infection during treatment. The research goes on to show that a third of all cancer patients require surgery as part of their treatment, 5% of whom will contract a potentially life-threatening resistant infection.”


Meunier, A., Nerich, V., Fagnoni-Legat, C., Richard, M., Mazel, D., Adotevi, O., Bertrand, X. & Hocquet, D. 2019.

BACKGROUND: Infections with antibiotic-resistant pathogens in cancer patients are a leading cause of mortality. Cancer patients are treated with compounds that can damage bacterial DNA, potentially triggering the SOS response, which in turn enhances the bacterial mutation rate. Antibiotic resistance readily occurs after mutation of bacterial core genes. Thus, we tested whether cancer chemotherapy drugs enhance the emergence of resistant mutants in commensal bacteria.

METHODS: Induction of the SOS response was tested after the incubation of *Escherichia coli* biosensors with 39 chemotherapeutic drugs at therapeutic concentrations. The mutation frequency was assessed after induction with the SOS-inducing chemotherapeutic drugs. We then tested the ability of the three most highly inducing drugs to drive the emergence of resistant mutants of major bacterial pathogens to first-line antibiotics.

RESULTS: Ten chemotherapeutic drugs activated the SOS response. Among them, eight accelerated the evolution of the major commensal *E. coli*, mostly through activation of the SOS response, with dacarbazine, azacitidine and streptozotocin enhancing the mutation rate 21.3-fold ($P < 0.001$), 101.7-fold ($P = 0.01$) and 1158.7-fold ($P = 0.02$), respectively. These three compounds also spurred the emergence of imipenem-resistant *Pseudomonas aeruginosa* (up to 6.21-fold; $P = 0.05$), ciprofloxacin-resistant *Staphylococcus aureus* (up to 57.72-fold; $P = 0.016$) and cefotaxime-resistant *Enterobacteria cloacae* (up to 4.57-fold; $P = 0.018$).

CONCLUSIONS: Our results suggest that chemotherapy could accelerate evolution of the microbiota and drive the emergence of antibiotic-resistant mutants from bacterial commensals in patients. This reveals an additional level of complexity of the interactions between cancer, chemotherapy and the gut microbiota.



[Picture Credit: How Antibiotic Resistance Spreads]

Very Few Antimicrobial and Antibiotic Drugs Being Developed

“The period from 1950 to 1960 was truly the golden age of antibiotic discovery, as one-half of the drugs commonly used today were discovered in this period. Unfortunately, the increasing use of antibiotics for human and nontherapeutic animal use (growth promotion) led all too soon to the development of resistant bacterial pathogens. Recognizing the correlation between antibiotic use and resistance development, much of subsequent antibiotic research has been devoted to the discovery and design of new compounds effective against the successive generations of resistant pathogens. It is interesting to note that microbial geneticists in the 1950s thought that the development of antibiotic-resistant strains concomitant with antibiotic use would be an unlikely and rare event at most!” (Davies, 2006).

Davies (2006) concludes: “Antibiotic resistance has occurred in our lifetimes. Within two to three years after the introduction of a new antibiotic treatment, resistance usually develops (although there have been a few notable exceptions – penicillin resistance in streptococci, for example). Nonetheless, antibiotics are an irreplaceable component in the control and treatment of infectious diseases; we cannot do without them.”



[Picture Credit: Antibiotics II]

Antibiotic Resistance and Treatment of Cancer Patients

Bacterial infection is one of the most frequent complications in cancer patients and haematopoietic stem cell transplant recipients. The emergence of antimicrobial resistance has become a significant problem worldwide, and cancer patients are among those that may be seriously affected. Antibiotics are the main line of defence when one's immune system is overwhelmed by bacteria. Bacterial infections can affect anyone, but the old, the young, the sick, and cancer patients are particularly vulnerable.

(Gudiol & Carratalà, 2014).

Cancer treatments increase the risk of getting an infection, so antibiotics are an essential part of treating cancer patients. Many cancer patients need antibiotics during all stages of their treatment.

Surgery	Radiotherapy	Chemotherapy
<p>Usually used to remove tumours.</p> <p>At least 5% of patients develop an infection.</p> <p>Infections can cause pain, longer hospital stays, and longer recovery time.</p> <p>Infections can make cancer treatments less successful.</p>	<p>Used to kill cancer cells, but can damage nearby healthy cells.</p> <p>Cells in hair, skin, and mouth and gut linings are most affected by this. Loss of these protecting cells increase the risk of getting an infection for which an antibiotic would be needed.</p>	<p>Used to stop the growth of cancer cells.</p> <p>Weakens the immune system and increases the risk of getting an infection.</p> <p>Infections can get worse quickly and cause severe illness.</p> <p>Infections can delay further chemotherapy sessions and make cancer treatment less successful</p>
<p>Antibiotics are crucial for controlling these infections and improving survival rates.</p>		

Antibiotic resistance poses a threat to everyone, but cancer patients are at particular risk. Cancer is typically treated with surgery, radiation, chemotherapy, and/or transplantation of bone marrow or blood stem cells. Each of these treatment techniques leaves a patient more vulnerable to infection than is a healthy adult of similar age.

According to the South African National Cancer Registry (2013), one in nine women and one in six men have a lifetime (0-74) risk of developing a cancer.

Antibiotic-Resistant Gram-Negative Bacterial Infections in Patients With Cancer

According to Perez, et al., 2016, a dramatic evolution has occurred in the significance of infections caused by gram-negative bacteria. Decades of progress in the care of patients with cancer, concomitant to the development of safe and effective antimicrobials, are being undermined. Patients with cancer, particularly those with haematologic malignancies, remain exquisitely vulnerable to infection with gram-negative bacteria as a result of neutropenia, lymphocyte dysfunction, mucositis, and the use of invasive devices.



[Picture Credit: Seek Qualified Advice]

You Can, I Can

There is not something which everyone **CAN** do
 There is actually something that everyone **MUST** do

And that is:

Do not ask, and do not expect, antibiotics for colds, sore throats, or flu
 Colds, sore throats, and flu are caused by viruses and antibiotics do not work

Only take antibiotics prescribed by a doctor


Use antibiotics EXACTLY as prescribed on the container

Always complete the full course of antibiotics

Never give or share antibiotics with others

The good news is that by doing something very simple
 everyone can do something very good -
 everyone can, in a very concrete way help cancer patients,
 now and into the future

(ANON)



[Picture Credit: Genetic Mutation Causes Drug Resistance]

Medical Disclaimer

This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (CANSA) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst the Cancer Association of South Africa (CANSA) has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.



Sources and References Consulted and/or Utilised

Antibiotic Action

http://antibiotic-action.com/wp-content/uploads/2015/07/Cancer-Fact-Sheet_14.07.15.pdf

Antibiotic Resistance

<http://www.pharmacist.com/working-prevent-antibiotic-resistance>

Antibiotics I

<http://www.who.int/drugresistance/en/>

Antibiotics II

<http://www.ibtimes.com/antibiotic-resistance-why-arent-drug-companies-developing-new-medicines-stop-1833248>

Combat Drug Resistance

<https://www.k4health.org/blog/archive/201511>

Davies, J. 2006. Where have all the antibiotics Gone? *Can J Infect Dis Med Microbiol.* 2006 Sep-Oct; 17(5):287-290. PMID: PMC2095086.

De Silva, N., Jackson, J. & Steer. 2018. Infections, resistance patterns and antibiotic use in patients at a regional cancer centre. *Intern Med J.* 2018 Mar;48(3):323-329. doi: 10.1111/imj.13646.

Drug Resistance

<https://www.wired.com/2011/04/resistance-what-works/>

Frieden, T. 2013. Meeting the Challenges of Drug-resistant Diseases in Developing Countries. <http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf>

Genetic Mutation Causes Drug Resistance

<https://www.vox.com/2015/2/17/8046605/antibiotic-resistance>

Gudiol, C. & Carratalà, J. 2014. Antibiotic resistance in cancer patients. *Expert Rev Anti Infect Ther.* 2014 Aug;12(8):1003-16. doi: 10.1586/14787210.2014.920253. Epub 2014 May 16.

How Antibiotic Resistance Spreads

<https://www.cdc.gov/antibiotic-use/community/about/antibiotic-resistance-faqs.html>

International Business Times

<http://www.ibtimes.com/antibiotic-resistance-why-arent-drug-companies-developing-new-medicines-stop-1833248>

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

March 2020

Keep Antibiotics Working

http://www.iatp.org/files/Antibiotic_Resistance_and_its_Impact_on_Cancer.pdf

Kreftforeningen, PB 4 Sentrum, 0101 Oslo. 2020. What are the consequences of antibiotic resistance for cancer patients? <https://kreftforeningen.no/antimicrobial-resistance/the-consequences-for-cancer-patients/>

Longitude Prize

<https://longitudeprize.org/blog-post/tackling-antibiotic-resistance-%E2%80%93-impact-cancer-patients>

MedScape Multispecialty

<http://www.medscape.com/viewarticle/488335>

McKenzie, J. 2017.

<https://www.newscientist.com/article/mg23231044-000-antibiotic-resistance-will-hit-a-terrible-tipping-point-in-2017/>

Meunier, A., Nerich, V., Fagnoni-Legat, C., Richard, M., Mazel, D., Adotevi, O., Bertrand, X. & Hocquet, D. 2019. Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs. *J Antimicrob Chemother.* 2019 Feb 20. pii: dkz070. doi: 10.1093/jac/dkz070. [Epub ahead of print].

Montserrat-Martinez, A., Gambin, Y. & Sierceki, I. 2019. Thinking outside the bug: molecular targets and strategies to overcome antibiotic resistance. *Int J Mol Sci.* 2019 Mar 13;20(6). pii: E1255. doi: 10.3390/ijms20061255.

Papanicolas, L.E., Gordon, D.L., Wesselingh, S.L. & Rogers, G.B. 2018. Not just antibiotics: is cancer chemotherapy driving antimicrobial resistance? *Trends Microbiol.* 2018 May;26(5):393-400. doi: 10.1016/j.tim.2017.10.009. Epub 2017 Nov 13.

Perez, C.F., Adachi, J. & Bonomo, R.A. 2016. Antibiotic-Resistant Gram-Negative Bacterial Infections in Patients With Cancer. <http://cid.oxfordjournals.org/>

Seek Qualified Advice

<http://www.who.int/antimicrobial-resistance/en/>

Technology Networks. 2020. Antibiotic Resistance Calls Future of Cancer Treatment Into Question. Feb 20, 2020. <https://www.technologynetworks.com/immunology/news/antibiotic-resistance-calls-future-of-cancer-treatment-into-question-331066>

Teillant, A., Gandra, S., Barter, D., Morgan, D.J. & Laxminarayan, R. 2015. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. *The Lancet.* ID-D-15-00510R1 S1473-3099(15)00270-4.

The Institute for Cancer Research

<http://www.icr.ac.uk/blogs/science-talk-the-icr-blog/page-details/what-s-the-link-between-antibiotic-resistance-and-cancer-treatment->

World Health Organization 2017

<http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/>

<http://www.who.int/mediacentre/factsheets/fs194/en/>